US · WGSWW
GeneDx Holdings Corp.
- Sector
- Healthcare · Medical - Healthcare Information Services
- Headquarters
- Stamford, DE 06902
- Website
- genedx.com
Price · as of 2025-12-31
$0.01
Market cap 249.19K
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $131.72 | +2,124,416.13% |
| Intrinsic Value(DCF) | $1.10 | +17,641.94% |
| Graham-Dodd Method(GD) | $7.05 | +113,593.55% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $0.00 | $0.00 | |||
| 2022 | $0.00 | $0.00 | |||
| 2023 | $0.00 | $35.27 | |||
| 2024 | $0.00 | $0.00 | |||
| 2025 | $0.01 | $131.72 | $1.34 | $7.05 | $0.00 |
AI valuation
Our deep-learning model estimates GeneDx Holdings Corp.'s (WGSWW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $131.72
- Current price
- $0.01
- AI upside
- +2,124,416.13%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.10
+17,641.94% upside
Graham-Dodd
$7.05
+113,593.55% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| WGSWW | GeneDx Holdings Corp. | $0.01 | 249.19K | +2,124,416% | +17,642% | +113,594% | — | -0.02 | 0.00 | 0.00 | -2.86 | — | 0.00 | 69.74% | -2.76% | -4.92% | -7.60% | -4.61% | -4.25% | 0.49 | -4.65 | 2.46 | 2.26 | 7.09 | -6237.00% | 3997.00% | -14196.00% | 3871.23% | 0.31 | 5.60% | 0.00% | 0.00% | 0.00% | 1.61 | -1.33 | -0.04 | -2.35 |
| BJDX | Bluejay Diagnostics, Inc. | $2.05 | 929.76K | — | — | — | — | -0.10 | 0.13 | — | 0.49 | -0.17 | 0.13 | 0.00% | — | — | -178.98% | -533.23% | -133.92% | 0.04 | -8.71 | 6.05 | 5.33 | 0.61 | 5724.00% | — | -989.00% | -1057.58% | -9.65 | -604.40% | 0.00% | 0.00% | 289.45% | 0.46 | 0.41 | — | -9.61 |
| EUDA | EUDA Health Holdings Limi… | $0.97 | 36.85M | +2,936% | +48% | — | — | -6.66 | -45.90 | 29.21 | -6.78 | -97.63 | -40.54 | 19.00% | -432.19% | -382.87% | 350.26% | 594.47% | -1157.93% | -0.50 | -386.17 | 0.18 | 0.10 | -0.06 | 682.00% | 822.00% | -2629.00% | -1.84% | -0.49 | 73.77% | 0.00% | 0.00% | 1.84% | -6.82 | -54.96 | 29.47 | -57.29 |
| GLMD | Galmed Pharmaceuticals Lt… | $0.61 | 3.35M | — | — | — | — | -0.23 | 0.11 | — | 1.83 | — | 0.11 | 0.00% | — | — | -49.77% | -552.15% | -42.80% | 0.00 | -418.53 | 7.42 | 7.15 | 0.63 | -7302.00% | — | -419.00% | -334.59% | -2.71 | -517.15% | 0.00% | 0.00% | 104.25% | 2.16 | 2.31 | — | -14.90 |
| ISPC | iSpecimen Inc. | $0.25 | 1.39M | +15,728% | +124% | — | — | -0.08 | 0.30 | 0.11 | 0.04 | — | -0.50 | 42.93% | -136.99% | -134.51% | -191.51% | -381.28% | -99.31% | 0.09 | -57.84 | 0.62 | 0.58 | 0.12 | -2839.00% | -642.00% | -2115.00% | -830.12% | -1.43 | -249.24% | 0.00% | 0.00% | 0.00% | 0.04 | 0.07 | -0.06 | -14.44 |
| MLEC | Moolec Science S.A. | $13.30 | 9.66M | +7,515% | +24,189,467% | — | — | -0.07 | -0.12 | 0.02 | -3.56 | 0.00 | -0.05 | 34.17% | -3.14% | -33.41% | 376.84% | -11.15% | -93.08% | -3.74 | -0.25 | 0.13 | 0.12 | -3.57 | 897895.00% | 583074.00% | 21733.00% | -393.07% | -0.10 | -32.03% | 0.00% | 0.00% | 12.10% | -23.43 | -8.16 | 0.74 | -0.48 |
| MSPR | MSP Recovery, Inc. | $0.04 | 537.2K | +14,182% | +17,977% | — | — | -0.01 | 0.14 | 0.76 | -1.22 | -0.01 | -0.01 | 47.36% | -6982.79% | -1975.45% | -834.83% | -139.81% | -61.30% | 7.90 | -3.03 | 0.01 | 0.01 | -1.20 | 12779.00% | 13685.00% | -6014.00% | -119.26% | -0.01 | -1.83% | 0.00% | 0.00% | 0.00% | -0.62 | -47.84 | 43.63 | -3.28 |
| TIVC | Tivic Health Systems, Inc… | $0.82 | 889.68K | +3,622% | +81% | — | -43% | -189.04 | 421.70 | 1370.53 | -200.98 | — | 421.70 | 0.26% | -725.77% | -725.00% | -184.96% | -1041.58% | -142.01% | 0.00 | — | 9.70 | 7.61 | 0.38 | -8887.00% | -3367.00% | -3365.00% | -0.54% | -21.05 | -1053.36% | 0.00% | 0.00% | 0.00% | -188.49 | -186.38 | 1367.97 | 2331.04 |
| ZCMD | Zhongchao Inc. | $0.22 | 1.01M | +3,235,978% | +2,370% | +1,460% | +439% | -182.77 | 2.40 | 3.15 | 420.07 | — | 2.40 | 56.18% | -2.15% | -4.05% | -1.41% | -2.07% | -1.09% | 0.00 | — | 12.22 | 11.67 | -88.50 | -9724.00% | -1837.00% | 47522.00% | -9.04% | -0.96 | -68.56% | 0.00% | 0.00% | 2.09% | -108.26 | -8.18 | 2.33 | 18.23 |
About GeneDx Holdings Corp.
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
- CEO
- Katherine A. Stueland
- Employees
- 1K
- Beta
- 2.02
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.10 ÷ $0.01) − 1 = +17,641.94% (DCF, example).